What happens when a trusted healthcare provider dispenses a drug linked to brain tumors without fully disclosing the risks? A growing number of California women are asking that question in light of new legal investigations into Kaiser Permanente’s widespread use of Depo-Provera, a long-acting contraceptive now associated with a significantly increased risk of intracranial meningiomas. With lawsuits mounting and troubling medical histories coming to light, Kaiser faces scrutiny not only for the drug’s potential dangers, but also for what patients were—and weren’t—told.
As legal experts dig deeper, a troubling picture emerges of missed warnings, vulnerable patients, and a battle for accountability now playing out in both courtrooms and private arbitration.
Depo-Provera, whose active ingredient is medroxyprogesterone acetate, was first synthesized in the 1950s by the Upjohn Company (now part of Pfizer). Initially, it was used to treat endometrial and renal cancer. Its contraceptive properties were then recognized, leading to its use as a long-acting injectable birth control.
Clinical trials for Depo-Provera as a contraceptive began in the mid-1960s. However, these trials faced ethical criticism because it was alleged they targeted vulnerable populations without proper informed consent. The FDA rejected Depo-Provera’s approval as a contraceptive in the 1970s and 1980s, citing concerns about cancer risks and the ethical conduct of clinical trials. However, it was approved for contraception in several international markets, including France, as early as 1969. The FDA finally approved Depo-Provera for contraceptive use in the United States in 1992, acknowledging potential side effects such as bone density loss and menstrual irregularities.
Recent studies have established a significant association between long-term Depo-Provera use and an increased risk of developing intracranial meningiomas, which are typically benign brain tumors. A 2024 study found that women who used Depo-Provera for more than one year were over five times more likely to develop meningiomas requiring surgery compared to non-users, with higher cumulative doses over longer periods showing stronger associations.
Through the years, Kaiser Permanente has been a major provider of Depo-Provera to its members, administering the drug as a quarterly injection for contraception. Many Kaiser members have received Depo-Provera for periods exceeding one year, which is the threshold associated with increased meningioma risk.
Recent legal investigations have focused on whether Kaiser and the drug’s manufacturer, Pfizer, adequately warned patients and healthcare providers about the potential risk of developing meningiomas. Lawsuits in California have specifically involved Kaiser members who developed meningiomas after receiving Depo-Provera through the health plan. Because Kaiser played a significant role in the widespread use and distribution of Depo-Provera in California, it is now facing legal challenges related to side effects and the adequacy of patient warnings.
The first Depo-Provera meningioma lawsuits, filed in France, have resulted in regulatory changes in the European market: Meningioma risk is now listed on Depo-Provera's warning labels, and some countries have implemented dosage restrictions.
In California, Kaiser requires all legal claims to be resolved through private arbitration, not civil lawsuits.
- If a patient’s claim is related to medical malpractice, the case goes to arbitration.
- If the claim is against the product manufacturer, the legal battle can be filed in Superior Court.
Pfizer argues that doctors and hospitals are responsible for informing patients of risks under what is called “the learned intermediary doctrine “. Under this rule, doctors may attempt to shift the blame back to the manufacturer if they were not adequately warned. This legal "blame game" creates a scenario where both Pfizer and Kaiser could deny liability, potentially leading to cases where plaintiffs lose on both fronts.
Walkup, Melodia, Kelly & Schoenberger has long been a leader in litigation against Kaiser, successfully holding the HMO accountable for medical negligence. Walkup attorneys are currently investigating whether Kaiser failed to adequately warn patients about the risk of meningiomas associated with long-term Depo-Provera use.
“Patients trust their healthcare providers to put safety first, but too often, corporate interests take precedence over patient well-being,” said Walkup Shareholder Michael A. Kelly. “If Kaiser downplayed or ignored the risks of Depo-Provera, we intend to hold them accountable.”
For decades, Walkup attorneys have won landmark arbitration verdicts and settlements for patients harmed by medical negligence, from misdiagnosed medical conditions to surgical errors to dangerous prescription policies. The emerging evidence surrounding Depo-Provera and meningioma risk suggests yet another instance in which Kaiser may have prioritized cost and convenience over patient safety.
"Over the years, we have represented plaintiffs in Kaiser arbitration cases involving cardiology, emergency medicine, neurosurgery, obstetrics, and mental health care failures. Knowing how to work within Kaiser’s arbitration system is critical to securing justice for health plan members who have suffered from medical negligence," said Kelly.
Legal claims against Kaiser for injuries due to Depo-Provera are active and expanding, with allegations centered on failure to warn about the risk of meningioma brain tumors. The litigation is in its early stages, and California is a central jurisdiction for state court filings.
Copyright © 2025 California Business Journal. All Rights Reserved.
